Treatment of hepatitis C virus genotype 1-infected patients: Mission accomplished?

Liver International

Volumn 36, Issue 2, 2016, Pages 181-184

  Puoti, Massimo ^a   Rossotti, Roberto ^a   Baiguera, Chiara ^a   Orso, Maurizio ^a  

^a Center of Cognitive Neuropsychology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 5A; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERTRANSAMINASEMIA; NONHUMAN; TREATMENT DURATION; CHRONIC HEPATITIS C; COMMUNITY CARE; GENETICS; GENOTYPE; HEPACIVIRUS; VIROLOGY;

GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; RELIGIOUS MISSIONS;

EID: 84955514203     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13040     Document Type: Editorial

References (20)

1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87.
2. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932-54.
3. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
4. Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 2015; 62: 25-30.
5. Reddy KR, Bourlière M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015; 62: 79-86.
6. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-603.
7. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-14.
8. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.
9. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% SVR with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 14: 359-365.
10. Everson GT, Sims KD, Thuluvath PJ, et al. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int 2016; 36: 189-197.
11. Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015; 313: 1736-44.
12. Poordad F, Sievert W, Mollison L, et al. Therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015; 313: 1728-35.
13. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163: 1-13.
14. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373: 2599-607.
15. Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015; 163: 809-17.
16. Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015; 163: 818-26.
17. Poordad F, Felizarta F, Asatryan A, et al. 98%-100% SVR4 in HCV genotype 1 non-cirrhotic treatment-naïve or pegylated interferon/ribavirin null responders with the combination of the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 (SURVEYOR-1). Hepatology 2015; 62(Suppl. 1): 228A-9A.
18. Poordad F, Felizarta F, Asatryan A, et al. 98%-100% SVR4 in HCV genotype 1 non-cirrhotic treatment-naïve or pegylated interferon/ribavirin null responders with the combination of the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 (SURVEYOR-1). Hepatology 2015; 62(Suppl 1): 1388A.
19. Gane EJ, Hyland RH, Yang Y, et al. Sofosbuvir/GS-5816 + GS-9857 for 6 or 8 weeks in genotype 1 or 3 HCV-infected patients. Hepatology 2015; 62(Suppl. 1): 226A.
20. Tatham LM, Rannard SP, Owen A. Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics. Ther Deliv 2015; 6: 469-90.